Literature DB >> 9301986

Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.

M A Schouten1, J A Hoogkamp-Korstanje.   

Abstract

The in-vitro activity of quinupristin-dalfopristin was compared with those of vancomycin, teicoplanin, erythromycin, clarithromycin, rifampicin, imipenem, meropenem, ciprofloxacin and sparfloxacin against 414 bloodstream isolates of Gram-positive cocci. Quinupristin-dalfopristin inhibited strains of Streptococcus pyogenes and Streptococcus agalactiae at 0.12 mg/L, methicillin- and/or erythromycin-resistant Staphylococcus aureus and Staphylococcus epidermidis at 0.5 mg/L, Staphylococcus haemolyticus, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus mitis, Streptococcus bovis, Streptococcus sanguis and Streptococcus anginosus at 1 mg/L and Enterococcus faecalis at 8 mg/L.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301986     DOI: 10.1093/jac/40.2.213

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.

Authors:  M A Schouten; A Voss; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

4.  Prevalence and antimicrobial resistance of Enterococcus species: a hospital-based study in China.

Authors:  Wei Jia; Gang Li; Wen Wang
Journal:  Int J Environ Res Public Health       Date:  2014-03-21       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.